Novo Nordisk’s recent trial results for their obesity drug candidate, CagriSema, have sparked concerns among investors. Intended as a successor to the successful Wegovy, CagriSema aimed to surpass Eli Lilly’s Mounjaro. However, findings showed a 13.7% weight reduction, not enough to outpace Mounjaro’s influence in the market.
About the Author
